Exact Sciences' (EXAS) Outperform Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Exact Sciences (NASDAQ:EXAS - Free Report) in a report released on Thursday,RTT News reports.

Other analysts have also issued reports about the company. TD Cowen boosted their price objective on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Robert W. Baird dropped their target price on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Piper Sandler cut their price target on Exact Sciences from $85.00 to $75.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. Finally, Canaccord Genuity Group lowered their price objective on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Exact Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $72.06.

Exact Sciences Stock Down 0.5 %

Shares of Exact Sciences stock traded down $0.25 on Thursday, hitting $49.26. 3,339,540 shares of the company's stock traded hands, compared to its average volume of 2,338,169. Exact Sciences has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The stock has a market cap of $9.12 billion, a P/E ratio of -8.84 and a beta of 1.24. The firm's 50-day moving average is $54.91 and its 200 day moving average is $59.99.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 4.97%. Equities analysts anticipate that Exact Sciences will post -0.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Huntington National Bank boosted its stake in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in shares of Exact Sciences during the third quarter valued at $34,000. Capital Performance Advisors LLP acquired a new position in shares of Exact Sciences in the 3rd quarter valued at $35,000. Asset Planning Inc purchased a new position in Exact Sciences in the 4th quarter worth about $40,000. Finally, Modus Advisors LLC acquired a new stake in Exact Sciences during the 4th quarter worth about $43,000. Institutional investors own 88.82% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.